Unlike the anti-PD-1 mAb treatment, it is unclear whether the anti-CTLA-4 mAb regimen mediates ICI-associated myocarditis development through the activation of autoreactive T cells targeting cardiac myosin heavy chain. The gene discussed is PDCD1; the disease is myocarditis.